162 related articles for article (PubMed ID: 17302433)
1. P-Glycoprotein kinetics measured in plasma membrane vesicles and living cells.
Aänismaa P; Seelig A
Biochemistry; 2007 Mar; 46(11):3394-404. PubMed ID: 17302433
[TBL] [Abstract][Full Text] [Related]
2. The rate of P-glycoprotein activation depends on the metabolic state of the cell.
Gatlik-Landwojtowicz E; Aänismaa P; Seelig A
Biochemistry; 2004 Nov; 43(46):14840-51. PubMed ID: 15544355
[TBL] [Abstract][Full Text] [Related]
3. P-glycoprotein senses its substrates and the lateral membrane packing density: consequences for the catalytic cycle.
Aänismaa P; Gatlik-Landwojtowicz E; Seelig A
Biochemistry; 2008 Sep; 47(38):10197-207. PubMed ID: 18759452
[TBL] [Abstract][Full Text] [Related]
4. Quantification and characterization of P-glycoprotein-substrate interactions.
Gatlik-Landwojtowicz E; Aänismaa P; Seelig A
Biochemistry; 2006 Mar; 45(9):3020-32. PubMed ID: 16503657
[TBL] [Abstract][Full Text] [Related]
5. Kinetic evidence suggesting that the multidrug transporter differentially handles influx and efflux of its substrates.
Stein WD; Cardarelli C; Pastan I; Gottesman MM
Mol Pharmacol; 1994 Apr; 45(4):763-72. PubMed ID: 7910372
[TBL] [Abstract][Full Text] [Related]
6. ATP occlusion by P-glycoprotein as a surrogate measure for drug coupling.
Tombline G; Holt JJ; Gannon MK; Donnelly DJ; Wetzel B; Sawada GA; Raub TJ; Detty MR
Biochemistry; 2008 Mar; 47(10):3294-307. PubMed ID: 18275155
[TBL] [Abstract][Full Text] [Related]
7. P-glycoprotein substrate transport assessed by comparing cellular and vesicular ATPase activity.
Nervi P; Li-Blatter X; Aänismaa P; Seelig A
Biochim Biophys Acta; 2010 Mar; 1798(3):515-25. PubMed ID: 20004641
[TBL] [Abstract][Full Text] [Related]
8. Detergents as intrinsic P-glycoprotein substrates and inhibitors.
Li-Blatter X; Nervi P; Seelig A
Biochim Biophys Acta; 2009 Oct; 1788(10):2335-44. PubMed ID: 19631191
[TBL] [Abstract][Full Text] [Related]
9. ATP hydrolysis promotes interactions between the extracellular ends of transmembrane segments 1 and 11 of human multidrug resistance P-glycoprotein.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2005 Aug; 44(30):10250-8. PubMed ID: 16042402
[TBL] [Abstract][Full Text] [Related]
10. A continuous fluorescence assay for the study of P-glycoprotein-mediated drug efflux using inside-out membrane vesicles.
Bebawy M; Morris MB; Roufogalis BD
Anal Biochem; 1999 Mar; 268(2):270-7. PubMed ID: 10075817
[TBL] [Abstract][Full Text] [Related]
11. Interaction of tomato lectin with ABC transporter in cancer cells: glycosylation confers functional conformation of P-gp.
Molnár J; Kars MD; Gündüz U; Engi H; Schumacher U; Van Damme EJ; Peumans WJ; Makovitzky J; Gyémánt N; Molnár P
Acta Histochem; 2009; 111(4):329-33. PubMed ID: 19124148
[TBL] [Abstract][Full Text] [Related]
12. Modulation of drug-stimulated ATPase activity of human MDR1/P-glycoprotein by cholesterol.
Kimura Y; Kioka N; Kato H; Matsuo M; Ueda K
Biochem J; 2007 Jan; 401(2):597-605. PubMed ID: 17029589
[TBL] [Abstract][Full Text] [Related]
13. P-glycoprotein does not reduce substrate concentration from the extracellular leaflet of the plasma membrane in living cells.
Chen Y; Pant AC; Simon SM
Cancer Res; 2001 Nov; 61(21):7763-9. PubMed ID: 11691790
[TBL] [Abstract][Full Text] [Related]
14. The multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane.
Garrigues A; Escargueil AE; Orlowski S
Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10347-52. PubMed ID: 12145328
[TBL] [Abstract][Full Text] [Related]
15. Cholesterol interaction with the daunorubicin binding site of P-glycoprotein.
Wang E; Casciano CN; Clement RP; Johnson WW
Biochem Biophys Res Commun; 2000 Oct; 276(3):909-16. PubMed ID: 11027568
[TBL] [Abstract][Full Text] [Related]
16. Optimizing chemotherapy by measuring reversal of P-glycoprotein activity in plasma membrane vesicles.
Köhler S; Stein WD
Biotechnol Bioeng; 2003 Mar; 81(5):507-17. PubMed ID: 12514799
[TBL] [Abstract][Full Text] [Related]
17. Modulation by the ATP/GTP ratio of the phosphorylation level of P-glycoprotein and of various plasma membrane proteins of KB-V1 multidrug resistant cells.
Lelong-Rebel IH; Rebel G; Cardarelli CO; Pastan I; Gottesman MM
Anticancer Res; 2003; 23(3B):2363-75. PubMed ID: 12894516
[TBL] [Abstract][Full Text] [Related]
18. Biochemical basis of polyvalency as a strategy for enhancing the efficacy of P-glycoprotein (ABCB1) modulators: stipiamide homodimers separated with defined-length spacers reverse drug efflux with greater efficacy.
Sauna ZE; Andrus MB; Turner TM; Ambudkar SV
Biochemistry; 2004 Mar; 43(8):2262-71. PubMed ID: 14979722
[TBL] [Abstract][Full Text] [Related]
19. Nucleotide binding, ATP hydrolysis, and mutation of the catalytic carboxylates of human P-glycoprotein cause distinct conformational changes in the transmembrane segments.
Loo TW; Bartlett MC; Clarke DM
Biochemistry; 2007 Aug; 46(32):9328-36. PubMed ID: 17636884
[TBL] [Abstract][Full Text] [Related]
20. Modulation of cellular cholesterol alters P-glycoprotein activity in multidrug-resistant cells.
Troost J; Lindenmaier H; Haefeli WE; Weiss J
Mol Pharmacol; 2004 Nov; 66(5):1332-9. PubMed ID: 15308763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
